Combination treatment for recurrent respiratory papillomatosis
Treatments studied
Part of Cancer, Ear, nose & throat, Infections, Lungs & breathing clinical trials.
This trial tests combining two drugs, bevacizumab and PRGN-2012, to treat recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths come back in the airway. The goal is to see if the combination reduces the need for surgeries or other procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of RRP.
- You are 18 years or older.
- You have had at least 2 surgeries or IV bevacizumab treatment to control RRP in the last 12 months.
- You have previously been treated with PRGN-2012 (zopapogene imadenovec [Papzimeos]).
- You have a good performance status (ECOG 0-1) and adequate organ function (like blood counts, liver, and kidney).
- You agree to use effective contraception if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.
This early-phase trial tests how well pembrolizumab plus lenvatinib can treat respiratory papillomas that have spread to the lungs. It may help people whose lung disease is caused by human papillomavirus (HPV).
This study tests whether an extra dose of the Gardasil-9 vaccine can help reduce the number of surgeries needed for recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths recur in the airway. You may be eligible if you've had the vaccine before and still have frequent recurrences.
This Phase 1 trial is testing a vaccine made from your own immune cells (dendritic cells) that may help your body fight the virus causing recurrent papillomas in your voice box. It is for people whose papillomas are caused by HPV type 6, who have had at least one recurrence in the past year.
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Hear when a new Human Papillomavirus (HPV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.